Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols

Pediatric Hematology and Oncology

Volumn 25, Issue 3, 2008, Pages 195-204

  Yilmaz, Şebnem ^a   Ören, Hale ^a   Demircioǧlu, Fatih ^a   Irken, Gülersu ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Febrile neutropenia; Granulocyte colony stimulating factor; Leukemia

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CEFTAZIDIME; COTRIMOXAZOLE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MEROPENEM; TEICOPLANIN; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ANTIMICROBIAL THERAPY; ARTICLE; AUTHOR; BACTEREMIA; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE DURATION; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INFANT; LABORATORY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYCOSIS; PEDIATRICS; PREDICTION; RISK; SURVIVAL RATE; TIME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BACTEREMIA; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; MUCOSITIS; NEUTROPENIA; PREDNISONE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; VINCRISTINE;

EID: 42549161131     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010801938231     Document Type: Article

References (37)

1. Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer: a prospective study of 1001 episodes. Medicine. 1982;61:153-165.
2. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323-1332.
3. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99:580-588.
4. Quadri TL, Brown AE. Infectious complications in the critically ill patient with cancer. Semin Oncol. 2000;27:335-346.
5. Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002;24:38-42.
6. West DC, Marcin JP, Mawis R, et al. Children with cancer, fever, and treatment-induced neutropenia: risk factors associated with illness requiring the administration of critical care therapies. Pediatr Emerg Care. 2004;20:79-84.
7. Basu SK, Fernandez ID, Fisher SG, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23:7958-7966.
8. Jones GR, Konsler GK, Dunaway RP, et al. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr. 1994;124:703-708.
9. Schrappe M, Reiter M, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia. 2000;14:2205-2222.
10. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19:2030-2042.
11. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
12. Link H, Böhme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003;82(Suppl 2):S105-117.
13. Mayordomo JI, Rivera F, Díaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst. 1995;87:803-808.
14. Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol. 2002;39:77-85.
15. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19:3415-3421.
16. Rondinelli PI, Ribeiro Kde C, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006;28:665-670.
17. Reilly A. Infections in children with cancer-old approaches and new. Eur J Cancer. 2003;39:652-653.
18. Chanock SJ, Pizzo PA. Infectious complications of patients undergoing therapy for acute leukemia: current status and future prospects. Semin Oncol. 1997;24:132-140.
19. Ammann RA, Aebi C, Hirt A. Fever in neutropenia in children and adolescents: evolution over time of main characteristics in a single center, 1993-2001. Support Care Cancer. 2004;12:826-832.
20. Tezcan G, Küpesiz A, Özturk F, et al. Episodes of fever and neutropenia in children with cancer in a tertiary care medical center in Turkey. Pediatr Hematol Oncol. 2006;23:217-29.
21. Aksoylar S, Çetingül N, Kantar M, et al. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol. 2004;21:115-123.
22. Gençer S, Salepci T, Ozer S. Evaluation of infectious etiology and prognostic risk factors of febrile episodes in neutropenic cancer patients. J Infect. 2003;47:65-72.
23. Aǧaoǧlu L, Devecioǧlu O, Anak S, et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother. 2001;13:281-287.
24. Auletta JJ, O'Riordan MA, Nieder ML. Infections in children with cancer: a continued need for the comprehensive physical examination. J Pediatr Hematol Oncol. 1999;21:501-508.
25. Greenberg D, Moser A, Yagupsky P, et al. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int J Antimicrob Agents. 2005;25:469-473.
26. Gibson J, Johnson L, Snowdon L, et al. Trends in bacterial infections in febrile neutropenic patients: 1986-1992. Aust N Z J Med. 1994;24:374-377.
27. Aledo A, Heller G, Ren L, Gardner S, et al. Septicemia and septic shock in pediatric patients: 140 consecutive cases on a pediatric hematology-oncology service. J Pediatr Hematol Oncol. 1998;20:215-221.
28. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310-3322.
29. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in children with AML: analysis of the AML-BFM 93 clinical trial. Blood. 2002;100:244b.[abstr]
30. Müller J, Garami M, Constantin T, et al. Meropenem in the treatment of febrile neutropenic children. Pediatr Hematol Oncol. 2005;22:277-284.
31. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol. 1995;13:165-176.
32. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis. 1991;164:907-916.
33. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12:2471-2508.
34. Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198-4214.
35. Sasse EC, Sasse AD, Brandalise S, et al. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2005;3:CD004139.
36. Sung L, Nathan PC, Lange B, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol. 2004;22:3350-3356.
37. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499-4506.